In a move that follows an increasingly common trend in biopharma M&A, Novartis is shedding sites and staffers from the German ...

To foray into the lucrative obesity market, Merck MRK announced that it is in-licensing global rights to an investigational ...

Amgen discovers, develops, manufactures, and delivers human therapeutics worldwide. This biotech giant remains a top stock ...

We recently compiled a list of the 10 Dogs of the Dow Dividend Stocks to Invest in. In this article, we are going to take a ...

A charter school with a focus on life sciences curriculum has gotten approved from town leaders in Holly Springs.

Nonspecific anti-inflammatories like steroids might be entirely sidelined for mild-to-moderate chronic hand eczema now that three targeted topical agents are available.

Amgen's leukemia drug Blincyto infringes patents owned by Germany's Lindis Biotech, a Delaware federal jury said in a verdict ...

Merck has signed a licensing deal worth up to $2 billion for Chinese biotech Hansoh Pharma's experimental oral drug to treat ...

Pain has really been out of favor in the industry up until very recently,” said John Mulcahy, SiteOne Therapeutics’ CEO. The ...

Viridian's veligrotug shows promising results in treating TED patients, setting the stage for future growth in the ...

Merck signed a deal worth up to $2 billion with Hansoh Pharma to develop and sell the Chinese biotech's oral obesity drug ...

Truist Financial analyst Srikripa Devarakonda assigned a Buy rating to the stock today. The company’s shares closed yesterday at $4.64.Pick the ...